Presenters: We hosted WuXi Biologics's IR team with investors on Nov 20 at our Asia Healthcare Corporate Day 2025. Bottom line: Mgmt noted 1) new order momentum remains robust heading into 4Q, with management aiming for an acceleration in both revenue and earnings in 2026. Management said they will provide further clarity on revenue and project guidance at the industry conference in early 2026, with detailed updates to follow at the full-year earnings release in March. 2) The capex plan is progressing as sc ...